Based on different chiral diamine skeletons, a series of bifunctional primary amine-thiophosphoramides were synthesized and screened as the catalysts for the asymmetric Michael addition of acetone to both aromatic and aliphatic nitroolefins. Under the catalysis of a thiophosphoramide derived from 1,2-diphenylethane-1,2-diamine, the corresponding adducts were obtained in high yields (up to >99%) with
Remote control: stereoselective coordination of electron-deficient 2,2′-bipyridine ligands to Re(<scp>i</scp>) and Ir(<scp>iii</scp>) cores
作者:Kimberley Jerwood、Phoebe Lowy、Laura Deeming、Benson M. Kariuki、Paul D. Newman
DOI:10.1039/d1dt02928b
日期:——
Highly diastereoselective coordination of unsymmetrical cationic 2,2′-bipyridine ligands bearing a chiral amidinium substituent to [Re(CO)3Cl] and [Ir(PhPy)2]+ cores is reported. Binding strength and stereoselectivity have been correlated with the position of the amidinium group on the bipy. The 4-, 5- and 6-substituted ligands all produce C-[Re(CO)3(LH)Cl]X selectively, while only the 4-derivative gives
[EN] RORγ MODULATORS<br/>[FR] MODULATEURS DE ROR&Ggr;
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2015035278A1
公开(公告)日:2015-03-12
Described are RORγ modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
[EN] PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES<br/>[FR] INHIBITEURS DE JAK3 DE TYPE PYRROLOPYRIDAZINE ET LEUR UTILISATION POUR TRAITER LES MALADIES INFLAMMATOIRES ET AUTO-IMMUNES
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2012125886A1
公开(公告)日:2012-09-20
Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
Synthesis and catalytic activity of new chiral ligands based on a 1,3-cyclopentanediamine
作者:Hirokazu Urabe、Tetsuro Yamakawa、Fumie Sato
DOI:10.1016/s0957-4166(00)82302-2
日期:1992.1
(1R,3S)-1,2,2-Trimethyl-1,3-cyclopentanediamine and its derivatives have been prepared and utilized as chiral ligands for asymmetric addition reactions of organometallics to aldehydes.